COVID-19 and Cancer Consortium Registry
Purpose
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.
Conditions
- COVID-19
- Invasive Malignancy (Any Type)
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
• Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria: - Suspected (presumptive positive based on clinical presentation) or lab-confirmed COVID-19. - Current or past medical history of invasive malignancy (any type)
Exclusion Criteria
- Participants at international sites not explicitly listed below - Non-healthcare providers (or their proxies)
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Case-Only
- Time Perspective
- Prospective
More Details
- Status
- Active, not recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
Study Contact
Detailed Description
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate hypothesis-generating and hypothesis-supporting findings that are generalizable to the population at large. Specifically: I. Characterize patient factors, such as pre-existing comorbidities, baseline medication exposures, cancer type, status, and treatment, and demographic factors that are associated with short- and long-term outcomes of COVID-19 (laboratory-confirmed or presumptive), including severity and fatality, in patients with cancer. II. Describe cancer treatment modifications made in response to COVID-19, including dose adjustments, changes in symptom management, or temporary or permanent cessation. III. Evaluate the association of COVID-19 with cancer outcomes.